Baxter International Faces Class Action Over Alleged Misrepresentation of Novum LVP Infusion Pumps

Baxter International (BAX) has been hit with a class action lawsuit filed on October 16, 2025, by shareholders alleging the company misled investors about its Novum IQ Large Volume Pump (Novum LVP). The plaintiffs claim Baxter's stock was artificially inflated between February 23, 2022, and July 30, 2025, due to false statements regarding the pump's safety, efficacy, and market potential.

The Novum LVP, approved in Canada in 2020 and the U.S. in 2024, is a critical product for Baxter, controlling IV fluid delivery in medical settings. The lawsuit targets seven current and former executives, accusing them of omitting material risks and exaggerating the product's commercial prospects.

Investors who purchased BAX stock during the class period are now seeking compensation for losses tied to what they describe as a 'house of cards' growth narrative. The case underscores mounting scrutiny of corporate disclosures in the medtech sector.